The problem the study tackles is one of the most stubborn in cardiovascular medicine. Cardiac rehabilitation, which combines structured exercise, education, and psychosocial support, carries a Class IA recommendation in international guidelines for patients recovering from bypass surgery, and its benefits are well documented: better exercise capacity, improved cardiac function, and stronger psychological well-being. Yet participation remains dismal. Fewer than half of eligible patients in developed countries attend a program, and in developing nations the figure drops below 10 percent. The barriers are mundane but powerful: distance to the hospital, transportation costs, work schedules, and family obligations. Home-based telerehabilitation, delivered through wearable heart rate monitors, mobile applications, and periodic video or telephone consultations, has been proposed as a way around these obstacles, but rigorous real-world comparisons with careful confounding control have been scarce.

The research team screened the electronic health records of 288 adults aged 30 to 75 who underwent isolated CABG between February 2024 and February 2025, ultimately identifying 195 potentially eligible patients. After excluding 28 whose rehabilitation exposure could not be clearly documented, 167 patients formed the propensity-score estimation cohort: 56 who enrolled in home-based telerehabilitation, 54 in center-based rehabilitation, and 57 who received usual care without any formal program. The primary complete-case analysis then focused on the 105 patients, 35 per group, who completed full 12-week assessments. Because patients were not randomized, the investigators used generalized propensity scores and overlap weighting to adjust for 25 baseline covariates, ranging from age, sex, and body mass index to digital literacy, family support, distance to the rehabilitation center, and baseline fitness measures.

The home program itself was a carefully structured prescription rather than a casual suggestion to stay active. Patients received a wearable Polar H10 heart rate monitor paired with a dedicated mobile application and were asked to complete three aerobic sessions per week for 12 weeks, 36 sessions in total, each targeting 30 to 60 minutes of exercise at 60 to 80 percent of heart rate reserve, plus two weekly resistance training sessions. Intensity was progressed every two weeks based on heart rate response and perceived exertion on the Borg scale. Crucially, the researchers defined a session as completed only when at least 30 minutes of prescribed exercise at target intensity were objectively documented by the wearable device; app entries without valid sensor data did not count. Center-based patients attended the hospital’s outpatient program with the same prescription but under direct supervision with continuous ECG telemetry, and their adherence was verified through physiotherapist-signed attendance records and telemetry logs.

The headline result concerns adherence, the study’s primary implementation outcome. Patients in the home-based arm completed a mean of 87.7 percent of their prescribed sessions, compared with 78.5 percent in the center-based arm, an overlap-weighted difference of 9.1 percentage points with a 95 percent confidence interval of 4.4 to 13.7 and a P value below 0.001. The gap widened at the high end of the distribution: 78.6 percent of home-based patients achieved at least 80 percent completion, versus 44.4 percent of center-based patients, and 46.4 percent of the home group reached 90 percent or more, compared with just 13.0 percent of the center group. Home patients also logged more objectively verified exercise minutes overall, 1,578 versus 1,413, and more minutes at target intensity. Technical failures, such as lost or invalid wearable recordings, affected only 1.7 percent of prescribed home sessions.

On the key clinical outcome, the two delivery models proved remarkably close. Peak oxygen uptake, or VO2peak, measured by symptom-limited cardiopulmonary exercise testing on a cycle ergometer, rose from a baseline of roughly 18.3 to 18.4 mL/kg/min to about 23.1 to 23.6 mL/kg/min at 12 weeks in both rehabilitation groups. The adjusted difference between the home and center arms was a mere 0.17 mL/kg/min, with a confidence interval spanning −0.50 to 0.84 and a P value of 0.616, statistically indistinguishable from zero. Both active groups, however, dramatically outperformed usual care, which saw VO2peak inch up from 18.5 to 19.1 mL/kg/min; the adjusted advantages over control exceeded 4.0 mL/kg/min for both rehabilitation modalities. Given that lower VO2peak is strongly associated with increased mortality in cardiac populations, gains of that magnitude are clinically noteworthy.

Secondary outcomes told a consistent story. Six-minute walk distance improved by roughly 75 meters in both rehabilitation groups compared with control, with no meaningful difference between them. Left ventricular ejection fraction, measured by blinded readers using the biplane Simpson method, rose by about 4 to 5 percentage points in both active arms. Psychological measures moved in parallel: scores on the Hamilton Anxiety and Depression scales fell by 6 to 8 points in both rehabilitation groups while barely changing in usual care, and quality-of-life scores on the SF-36 physical and mental component summaries climbed by 16 to 22 points. Safety findings were reassuring in absolute terms: no major adverse cardiovascular events occurred in either rehabilitation group during the 12-week window, while two occurred among usual-care patients, though the small event counts precluded formal comparative safety inference. Exercise-related adverse events were uncommon and similar in character across both programs, including occasional chest pain, arrhythmia, and musculoskeletal complaints.

The investigators were careful about what their design can and cannot show. Because patients self-selected into each modality, unmeasured differences in motivation and preference may persist despite the extensive covariate adjustment, and the study was not powered or designed to formally test equivalence or non-inferiority between the two delivery models. Selection is a real concern: of the 195 potentially eligible patients, 46.2 percent were excluded from the complete-case analysis, and those excluded patients had fewer years of education, more frailty, lower employment rates, and markedly lower family support scores. The authors also note that the two delivery models differed not only in setting but in supervision intensity, with home patients exercising independently and receiving roughly 12 scheduled tele-consultations, so residual differences in how adherence was ascertained, device verification at home versus direct observation in center, cannot be fully excluded. Sensitivity analyses, including unweighted models, multiple imputation, restriction to a strict 11-to-13-week assessment window, and exclusion of crossovers, all produced directionally consistent estimates for the VO2peak comparison.

An exploratory analysis probing whether higher adherence drove better functional outcomes found a positive but non-significant association: each 10-percentage-point increase in adherence was associated with roughly 0.62 mL/kg/min greater VO2peak gain, with a confidence interval that just crossed zero. The authors explicitly caution against a causal reading, since healthier, more motivated, or faster-recovering patients may both complete more sessions and improve more, a classic healthy-adherer effect that observational data cannot untangle. The adherence-by-modality interaction was also non-significant, suggesting the adherence-outcome relationship did not differ meaningfully between the home and center programs.

What the study does establish is feasibility in routine practice. Among post-CABG patients who chose between the two options in a real clinical setting, home-based telerehabilitation delivered objectively verified adherence that exceeded center-based care and functional recovery that looked essentially identical at 12 weeks. For patients juggling work, travel, or caregiving obligations, the findings support offering a monitored home program as a legitimate alternative rather than a second-best compromise. The authors call for future work on clinical meaningfulness and cost-effectiveness, and longer follow-up will be needed to see whether early fitness gains translate into durable outcomes. But the message for the millions of bypass patients each year who cannot reach a hospital gym is clear: with a chest strap, a smartphone, and a structured prescription, the road to recovery may run straight through their living room.

Subject of Research: Home-based versus center-based cardiac rehabilitation adherence and functional outcomes after coronary artery bypass grafting

Article Title: Home-based telerehabilitation after CABG: higher objectively verified adherence and 12-week functional outcomes in a single-center observational cohort

Article References: Liu, Y., Wang, X., Wang, C., Zhang, M., Kong, M., Wang, M., Ma, J., & Liu, H. (2026). Home-based telerehabilitation after CABG: higher objectively verified adherence and 12-week functional outcomes in a single-center observational cohort. Frontiers in Cardiovascular Medicine, 13, Article 1947232. https://doi.org/10.3389/fcvm.2026.1947232

Image Credits: AI Generated

DOI: 10.3389/fcvm.2026.1947232

Keywords: cardiac rehabilitation, coronary artery bypass grafting, telerehabilitation, wearable sensors, adherence, VO2peak, observational cohort, cardiovascular medicine, propensity score analysis, exercise capacity, digital health, patient recovery

The VITAL trial, funded by the National Institute for Health and Care Research, enrolled 2,507 patients aged 50 and over who were undergoing major planned non-cardiac operations at 49 NHS hospitals. Participants were randomly allocated to receive either total intravenous anaesthesia, known as TIVA, delivered through a continuous infusion of the drug propofol, or a volatile anaesthetic such as sevoflurane or isoflurane, inhaled through a mask or breathing circuit during surgery. Both methods are used routinely to keep patients unconscious during the more than 1.5 million major non-cardiac operations performed in the UK each year, yet until now no large-scale British trial had determined whether one technique offered patients a better outcome than the other.

The trial’s primary measure of recovery was the number of days patients were alive and out of hospital in the 30 days following their operation. On this endpoint, the two groups were essentially indistinguishable. Rates of major complications, delirium and death assessed at 30 days, 90 days and six months were also similar between the two anaesthetic approaches, providing strong evidence that neither technique confers a survival or complication advantage over the other in this broad surgical population.

There was, however, a signal of modest benefit in the immediate aftermath of surgery. Patients who received TIVA reported lower rates of thirst, hoarseness, nausea and vomiting on the day after their operation. These symptoms, while rarely dangerous, contribute substantially to the discomfort of the first hours and days after a major operation, and the finding suggests that intravenous anaesthesia may offer a somewhat smoother and more comfortable early recovery, even if it does not change the overall trajectory of healing or discharge.

The debate between the two camps of anaesthetists has been running for years. Advocates of TIVA have argued that it offers a smoother recovery with less postoperative sickness and pain, while critics have pointed to rare risks associated with the technique, including the possibility that a patient may briefly regain awareness during surgery when anaesthesia is maintained by infusion alone. Proponents of volatile gases have countered that these agents allow anaesthetic depth to be monitored continuously through exhaled concentrations, providing a well-established margin of safety. The VITAL results indicate that, for most patients, neither argument tips the balance decisively.

A companion economic evaluation, published in the journal Anaesthesia, examined the financial dimension of the question. It found that the two techniques cost the NHS a similar amount and delivered comparable quality of life for patients over a six-month period. This matters because propofol infusions require syringe pumps and careful pharmacological management, while volatile agents carry ongoing procurement costs and, increasingly, environmental scrutiny. Taken together, the clinical and economic findings indicate that TIVA and inhalational anaesthesia are equivalent both in outcomes and in value for adults having major non-cardiac surgery.

Professor Joyce Yeung of Warwick Clinical Trials Unit, chief investigator of the VITAL trial, said the results resolve a question that has divided the specialty. For years, she noted, anaesthetists have debated which technique gives patients the best start to their recovery. What the trial shows, she said, is that for most patients having major surgery the two methods are equally viable. That is reassuring for patients, she added, and it means doctors can keep making the decision based on what is right for the person in front of them rather than on pressure to switch to a newer or supposedly superior technique.

The practical implication is that anaesthetic choice can continue to rest on patient preference, clinician expertise and local availability rather than on any mandate to adopt a single approach across the health service. Some patients may prefer the absence of a breathing mask and the reported reduction in nausea associated with intravenous delivery, while others may be better served by the titratable control offered by inhaled agents. The trial suggests that either path leads to a comparable recovery, freeing anaesthetists to tailor their technique to the individual rather than to a guideline.

The researchers are careful to acknowledge the limitations of their study. The trial was not blinded, which means patients and their carers knew which anaesthetic they had received, a factor that could influence patient-reported outcomes such as pain and nausea. All participants were treated within the NHS, so the findings may not transfer directly to health systems with different staffing, equipment or postoperative care pathways. The study also did not examine longer-term cancer outcomes, a question that has been raised in smaller studies, nor did it assess the environmental impact of the two techniques.

That environmental question is far from trivial. Volatile anaesthetic gases such as sevoflurane and isoflurane are potent greenhouse gases, and their routine release into the atmosphere has become an area of growing interest for sustainability-minded hospitals, with some trusts already reviewing their use. The VITAL findings do not settle this dimension of the debate, but they do clarify that any future shift away from volatile agents for environmental reasons would not need to be justified on grounds of patient recovery, since the two techniques are clinically interchangeable in that respect. For the millions of people who undergo major surgery each year, the message from this landmark trial is straightforward: the anaesthetic that keeps them safely asleep matters far less than the skill of the team delivering it.

Subject of Research: Comparison of total intravenous anaesthesia and volatile inhalational anaesthesia for recovery after major non-cardiac surgery

Article Title: Anaesthesia choice makes no difference for patient recovery after major surgery

Article References: Anaesthesia choice makes no difference for patient recovery after major surgery. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: anaesthesia, TIVA, propofol, sevoflurane, VITAL trial, major surgery, patient recovery, randomized controlled trial, NHS, postoperative outcomes, JAMA, health economics

The study, conducted by researchers at Mashhad University of Medical Sciences in Iran, enrolled 96 patients recovering from upper gastrointestinal bleeding and randomly assigned half to a telenursing intervention and half to routine care. The trial was prospectively registered in the Iranian Registry of Clinical Trials under number IRCT20201231049897N1, and it received ethics approval from the university’s ethics committee along with funding from the university’s Deputy of Research. The central question was whether a carefully choreographed month of remote nursing contact could measurably improve patients’ quality of life and their satisfaction with care, compared with the standard discharge experience.

The intervention itself combined three channels of communication. Patients received a self-care mobile application designed to guide them through the practical realities of recovery, including medication adherence, diet, warning signs of rebleeding, and activity pacing. They also took part in weekly telephone counseling sessions with nurses, providing an opportunity to ask questions, report symptoms, and receive individualized advice. Finally, a WhatsApp group connected participants with peers going through the same experience, adding a social dimension to the educational program. The control group received routine discharge care plus brief weekly telephone calls, but these calls were deliberately limited to controlling for the attention patients received from research staff, with no structured education, counseling, or digital content provided and no outcome data collected from them.

The primary outcome was health-related quality of life, measured with the Gastrointestinal Quality of Life Index, a validated instrument that captures symptoms, emotional status, physical function, and social aspects of digestive health. One month after discharge, the intervention group scored 116.02 on average, with a standard deviation of 15.05, while the control group averaged 95.10 with a standard deviation of 13.57. That gap of roughly 21 points was highly statistically significant, with a p-value below 0.001. Because patients inevitably start out with different baseline quality of life, the researchers also ran an analysis of covariance adjusting for initial scores, and the intervention effect remained robust, with F equal to 13.38 and a p-value of 0.001.

Satisfaction told a similar story. Using the Telenursing Interaction and Satisfaction Questionnaire, the team found that intervention patients rated their experience far more positively than controls, with mean scores of 77.39 versus 47.04, again a difference that was highly significant. Interestingly, the control group’s satisfaction scores reflect their contact with the study’s brief follow-up calls, which underscores how much the structured program, rather than mere telephone contact, drove the difference. Patients in the intervention arm also evaluated the mobile application itself using the Mobile Application Rating Scale, awarding it a mean score of 98.24 out of a possible maximum, with a standard deviation of 6.54, indicating that the digital tool was perceived as high quality across engagement, functionality, aesthetics, and information content.

Why would a month of phone calls and an app make such a large difference in how patients feel? The answer likely lies in the nature of recovery from upper gastrointestinal bleeding. Patients are typically discharged with strict instructions about avoiding nonsteroidal anti-inflammatory drugs, managing acid suppression therapy, and watching for signs of recurrent bleeding such as black stools or vomiting blood. Without reinforcement, these instructions are easy to forget or misunderstand, and anxiety about rebleeding can dominate daily life. Structured telenursing gives patients a reliable channel for clarifying doubts, and the peer group normalizes the worries and setbacks that accompany recovery, both of which plausibly translate into better perceived health and greater confidence in self-management.

The trial’s design deserves attention for how it handled the placebo problem inherent in behavioral interventions. Any extra contact with healthcare staff can make patients feel cared for, so a control group that receives nothing at all can exaggerate the apparent benefit of an intervention. By giving controls brief weekly calls purely to equalize the amount of attention between groups, the researchers isolated the effect of the structured educational content itself. The fact that a large difference in quality of life and satisfaction persisted despite this attention control strengthens the conclusion that the self-care education, not simply human contact, produced the gains.

The authors are careful about the limits of what their data show. Because the trial did not assess objective clinical outcomes such as recurrent bleeding, hospital readmission, or mortality, the results should be read as evidence of improved patient-reported recovery rather than proof of a better clinical prognosis. Quality of life and satisfaction are meaningful endpoints in their own right, and they are strongly associated with adherence and engagement with follow-up care, but a larger and longer trial would be needed to determine whether telenursing also reduces the risk of dangerous rebleeding episodes or keeps patients out of the emergency department.

Even with those caveats, the findings arrive at a moment when health systems worldwide are searching for scalable ways to support patients beyond hospital walls. Telenursing requires no exotic technology, only a phone line, a well-designed application, and nurses with time and training. The near-perfect app rating in this study suggests that when digital tools are built around genuine patient needs and paired with live human support, patients embrace them enthusiastically. For a condition like upper gastrointestinal bleeding, where the first month after discharge is a vulnerable window, that combination of automated guidance and personal counseling appears to fill a real gap in care.

The study also highlights the broader potential of nursing-led telehealth programs across chronic and acute gastrointestinal disease. If structured remote education can lift quality-of-life scores by more than 20 points in a month for bleeding patients, the same model could plausibly benefit people managing peptic ulcer disease, inflammatory bowel conditions, or recovery from other acute events. The trial’s open-access publication means that its intervention structure, outcome instruments, and statistical approach are available to any clinical team willing to replicate or adapt them. For now, the message for patients leaving the hospital after a gastrointestinal bleed is encouraging: a month of structured, nurse-guided self-care support, delivered largely through devices most people already own, can make the road back to normal life measurably smoother.

Subject of Research: Telenursing-based self-care education for patients recovering from upper gastrointestinal bleeding

Article Title: Telenursing-based self-care education improves quality of life and patient satisfaction in upper gastrointestinal bleeding: a randomized controlled trial

Article References: Lajevardi, R., Aghebati, N., Ghavami, V., & Rajabpour, M. (2026). Telenursing-based self-care education improves quality of life and patient satisfaction in upper gastrointestinal bleeding: a randomized controlled trial. BMC Nursing. https://doi.org/10.1186/s12912-026-05055-3

Image Credits: AI Generated

DOI: 10.1186/s12912-026-05055-3

Keywords: telenursing, telehealth, upper gastrointestinal bleeding, self-care education, quality of life, patient satisfaction, randomized controlled trial, mobile application, nursing, digital health, patient recovery, GIQLI